Preventive and therapeutic HPV vaccines

A. Monie, C. F. Hung, T. C. Wu

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Cervical cancer is the second leading cause of cancer deaths in women worldwide and HPV infection is responsible for the development of this cancer. Effective vaccination against HPV represents an opportunity for the control of cervical cancer. The newly licensed preventive HPV vaccine in the US, Gardasil, has both a good safety profile and clinical efficacy against the HPV genotypes from which it was derived. However, this vaccine can only protect against up to 70 to 80% of cervical cancer and also lacks therapeutic efficacy against established HPV infection and HPV-associated lesions. Thus, the future of HPV vaccination needs to focus on the development of a new generation of preventive and therapeutic vaccines that are capable of protecting against most cervical cancers.

Original languageEnglish (US)
Pages (from-to)1038-1050
Number of pages13
JournalCurrent Opinion in Investigational Drugs
Issue number12
StatePublished - Dec 12 2007


  • Cervical cancer
  • HPV
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Preventive and therapeutic HPV vaccines'. Together they form a unique fingerprint.

Cite this